Trial intelligence / Profile preview

Afinitor for Neurocognition in Tuberous Sclerosis Complex

NCT01289912Phase 2

Key facts

Status
Completed
Start
Jan 2011
Primary completion
Dec 2014
Countries
1
Modality
Small Molecules
Conditions
tuberous sclerosis complex (TSC)
01

Overview

Phase 2, randomised, double-blind trial of everolimus in tuberous sclerosis complex (TSC). Started Jan 2011; status: completed.

02

Design

Study design
RandomizedDouble-blind
03

Registry description

Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families. Investigators are doing research in order to identify possible neurocognitive benefits from treatment with RAD001 or placebo for a six month period. There may also be potential for improvements in seizure frequency, sleep and autistic behaviors. We hope this trial will lead to a better understanding of TSC and to new forms of treatment, to benefit children and adults with TSC in the…

Beyond the preview

Go deeper on NCT01289912.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01289912.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call